FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Executive Summary
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting
You may also be interested in...
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
All-Amgen Denosumab Raises Hopes; Proof-Of-Concept Peek Due At ASCO
If Amgen's denosumab works as well in Phase III as investors hope, the bone-building drug could become not only a bottom-line savior after the much-publicized trouble with erythropoietin stimulating agents, but could also become a matter of significant pride for its developers